Pharming Group Balance Sheet Health
Financial Health criteria checks 6/6
Pharming Group has a total shareholder equity of $264.6M and total debt of $98.3M, which brings its debt-to-equity ratio to 37.2%. Its total assets and total liabilities are $473.8M and $209.1M respectively. Pharming Group's EBIT is $41.5M making its interest coverage ratio 3.6. It has cash and short-term investments of $166.2M.
Key information
37.16%
Debt to equity ratio
US$98.35m
Debt
| Interest coverage ratio | 3.6x |
| Cash | US$166.17m |
| Equity | US$264.64m |
| Total liabilities | US$209.14m |
| Total assets | US$473.79m |
Recent financial health updates
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Nov 11
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Jun 20Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Mar 16We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease
Dec 08Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Aug 05Recent updates
Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Sep 08There's No Escaping Pharming Group N.V.'s (AMS:PHARM) Muted Revenues Despite A 29% Share Price Rise
May 10Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 21Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price
Feb 14Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Nov 11Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 23Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Jun 20Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Mar 16Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price
Feb 17We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease
Dec 08Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Aug 05Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next
Mar 21These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat
Mar 19Financial Position Analysis
Short Term Liabilities: PHARM's short term assets ($277.6M) exceed its short term liabilities ($87.9M).
Long Term Liabilities: PHARM's short term assets ($277.6M) exceed its long term liabilities ($121.2M).
Debt to Equity History and Analysis
Debt Level: PHARM has more cash than its total debt.
Reducing Debt: PHARM's debt to equity ratio has reduced from 89.4% to 37.2% over the past 5 years.
Debt Coverage: PHARM's debt is well covered by operating cash flow (54.2%).
Interest Coverage: PHARM's interest payments on its debt are well covered by EBIT (3.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/04 15:41 |
| End of Day Share Price | 2025/12/04 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharming Group N.V. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Savin | Edison Investment Research |
| Simon Scholes | First Berlin Equity Research GmbH |
| Joseph Pantginis | H.C. Wainwright & Co. |